Skip to main navigation Home Archived News Releases KEYWORD SEARCH Year 2021 Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference 11/23/21 Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management 11/19/21 Pacira BioSciences to Present at the Jefferies London Healthcare Conference 11/10/21 Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021 11/09/21 Pacira Files Lawsuit Against eVenus for Patent Infringement 11/08/21 Pacira BioSciences Reports Third Quarter 2021 Financial Results 11/03/21 Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition 11/02/21 Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021 10/27/21 Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management 10/11/21 Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL 10/08/21 Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL® 10/04/21 Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility 09/30/21 Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries 09/21/21 Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021 09/15/21 Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference 09/08/21 Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021 08/10/21 Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference 08/04/21 Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 08/03/21 Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process 08/02/21 New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty 07/29/21 Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021 07/20/21 Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 07/13/21 Pacira Announces EXPAREL Distribution Agreement with Eurofarma in Latin America 06/22/21 Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021 06/08/21 Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block 05/26/21 Pacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference 05/25/21 Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL 05/18/21 Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference 05/12/21 Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021 05/11/21 Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update 05/04/21 Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021 04/21/21 Pacira BioSciences Announces Investment in Spine BioPharma 04/20/21 Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology 04/14/21 Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021 04/07/21 Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients 03/22/21 Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021 03/09/21 Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference 03/03/21 Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results 02/25/21 Pacira to Report 2020 Financial Results on Thursday February 25, 2021 02/18/21 Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021 02/10/21 Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics 01/26/21 Pacira Reports Record Revenue for 2020 of $429.6 Million 01/07/21 Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference 01/06/21 SHAREHOLDER TOOLS Print Page RSS Feeds Email Alerts Contact Us Legal Site Map Privacy Notice EXPAREL® (bupivacaine liposome injectable suspension), the EXPAREL logo, ioverao, the ioverao logo, Pacira, and the Pacira logo are registered trademarks of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners. ©2021 Pacira BioSciences, Inc. | PP-EX-IO-US-0057 | 11/2021 This website uses cookies to give you a better browsing experience. By continuing to use this site you agree to our use of cookies. For additional information see our Cookie Notice.